Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELOX
DateTimeSourceHeadlineSymbolCompany
21/08/202400:13Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ELOXEloxx Pharmaceuticals Inc
11/07/202415:46GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Pipeline and Financing UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
16/04/202411:30GlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
01/04/202420:02Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
29/03/202420:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/03/202418:20Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/03/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
13/03/202415:42GlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
26/01/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
26/01/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
26/01/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
26/01/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
25/01/202402:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
24/01/202422:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/01/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
28/12/202321:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
13/11/202321:15GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
16/10/202321:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
09/10/202312:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
20/09/202320:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
20/09/202317:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
19/09/202312:00GlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
18/09/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
18/09/202311:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
15/09/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
07/09/202314:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
07/09/202313:00GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
29/08/202320:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
21/08/202320:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
14/08/202315:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELOX